SCHEMBL4831322

SCHEMBL4831322

CC(C)(C)OC(=O)C1(C(=O)OCc2ccccc2)CCCC1

nearest known ligand 0.46

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.45
DDB1 Q16531 1/20 0.45
CRBN Q96SW2 1/20 0.45
SYK P43405 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7228727 0.87 DDB1 (0.52) ALDH1A1DDB1CRBN
SCHEMBL18493339 0.85 DDB1 (0.54) ALDH1A1DDB1CRBN
SCHEMBL595870 0.82 DDB1 (0.51) ALDH1A1DDB1CRBN
SCHEMBL16661304 0.82 DDB1 (0.56) ALDH1A1DDB1CRBN
SCHEMBL13130080 0.82 TACR1 (0.50)
SCHEMBL4803125 0.81 DDB1 (0.48) ALDH1A1DDB1CRBN
SCHEMBL20457129 0.81 ALDH1A1 (0.53) ALDH1A1DDB1CRBN
SCHEMBL4429190 0.81 DDB1 (0.50) ALDH1A1DDB1CRBN
SCHEMBL2812229 0.80 MEN1 (0.43)
SCHEMBL27264102 0.80 CA12 (0.48) ALDH1A1DDB1CRBN

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11365192-B2 Pyridine compound substituted with azole TAISHO PHARMACEUTICAL CO., LTD. (JP) 2022-06-21 US disclosed
US-20210122741-A1 PYRIDINE COMPOUND SUBSTITUTED WITH AZOLE TAISHO PHARMACEUTICAL CO., LTD (JP) 2021-04-29 US disclosed
EP-3666766-A1 PYRIDINE COMPOUND SUBSTITUTED WITH AZOLE Taisho Pharmaceutical Co., Ltd. (JP) 2020-06-17 EP disclosed
CN-110914254-A Azole-substituted pyridine compound 大正制药株式会社 2020-03-24 CN disclosed
US-7348425-B2 Inhibitors of HCV replication BRISTOL-MYERS SQUIBB COMPANY (US) 2008-03-25 US disclosed
US-20060166964-A1 Inhibitors of HCV replication BRISTOL-MYERS SQUIBB COMPANY 2006-07-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210122741-A1 PYRIDINE COMPOUND SUBSTITUTED WITH AZOLE CYP2C19, CYP4A11, CYP11B1 ALDH1A1 378/4885DDB1 4819/4885CRBN 1881/4885
US-11365192-B2 Pyridine compound substituted with azole CYP2C19, CYP4A11, CYP11B1 ALDH1A1 378/4885DDB1 4819/4885CRBN 1881/4885
US-20060166964-A1 Inhibitors of HCV replication EIF2AK2, HCCS, IDO1 ALDH1A1 920/4885DDB1 1156/4885CRBN 2141/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.